# US 2008/0287544 A1 · Method for Screening Substance by Measuring PPAR DELTA Activating Effect and Agent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0287544 A1
- Document ID: US20080287544A1
- Status: Published application
- Kind: A1
- Application number: 12/142,652
- Filed: 2008-06-19
- Published: 2008-11-20
- Earliest claimed: 2001-07-17
- Assignees: Teijin Limited
- Inventors: Kazuyoshi YAMAOKA; Kenichiro Takagi; Kenichiro Kataoka; Masanori Yamamoto; Toshihiro Chikanishi
- Web page: https://patentgrep.com/patent/US20080287544A1

## CPC

- G01N 33/5079: {Mitochondria}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a method for screening a substance having a thermogenesis enhancing effect containing a compound having an effect activating PPARδ, an agent containing the compound, and an agent having antidiabetic, antiobestic or visceral accumulated fat-lowering function. The present invention provides an agent containing a compound having an effect activating PPARδ, which is a peroxisome proliferator activated receptor, and having effects which enhances nonshivering thermogenesis (nST), specifically enhances uncoupling respiration in mitochondria of cells in an adipose tissue or the like, or proton leak in inner membranes of mitochondria, and increases the amount of expression of UCP1, and provides an antidiabetic agent, an antiobestic gent and a visceral accumulated fat-lowering agent containing the compound. Further, the present invention provides a method for screening the compound by measuring a PPARδ activating effect.

## Claims

### Claim 1

A method of enhancing thermogenesis effect comprising administering to a subject in need thereof an effective amount of a substance having a PPARδ-activating effect.

### Claim 2

A method of enhancing uncoupling respiration in mitochondria comprising administering to a subject in need thereof an effective amount of a substance having a PPARδ-activating effect.

### Claim 3

A method of enhancing proton leak in internal membranes of mitochondria comprising administering to a subject in need thereof an effective amount of a substance having a PPARδ-activating effect.

### Claim 4

A method of increasing the amount of expression of UCP1 in mitochondria-containing cells comprising administering to a subject in need thereof an effective amount of a substance having a PPARδ-activating effect.

### Claim 5

A method of enhancing fatty acid β-oxidation comprising administering to a subject in need thereof an effective amount of a substance having a PPARδ-activating effect.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of according to any one of claims 1 to 5, wherein said substance having a PPARδ-activating effect is a nonspecific PPARδ ligand or a PPAR δ ligand.

### Claim 7 (depends on 1, 2, 3, 4, 5)

The method according to any one of claims 1 to 5, wherein said substance having a PPARδ-activating effect is carbaprostacyclin, iloprost or p—(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy)phenylacetic acid.

### Claim 8 (depends on 2, 3, 4)

The method of according to any one of claims 2 to 4, wherein said mitochondria exist in cells of a skeletal muscle, a white adipose tissue or a brown adipose tissue.

### Claim 9 (depends on 2, 3, 4)

The method of according to any one of claims 2 to 4, wherein said mitochondria exist in cells of a white adipose tissue or a brown adipose tissue.

### Claim 10

A method of treating obesity, diabetic, hypertension, hyperlipemia, arteriosclerosis or ischemic heart disease, a method of lowering the amount of visceral fat accumulation or a method of inhibiting visceral fat accumulation, comprising administering to a subject in need thereof an effective amount of an agent containing a substance having a PPARδ-activating effect as an active ingredient.

### Claim 11 (depends on 10)

The method of claim 10, wherein said substance having a PPARδ-activating effect is a nonspecific PPARδ ligand or a PPAR δ ligand.

### Claim 12 (depends on 10)

The method of claim 10, wherein said substance having a PPARδ-activating effect is carbaprostacyclin, iloprost or p—(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy)phenylacetic acid.
